is a biopharmaceutical company focused on improving the treatment of cardiovascular disease.
acquired from Pfizer Inc., manufactures and markets devices to surgically treat incontinence and impotence.
provides analytical testing services to the medical device and biopharmaceutical industries and manufactures protein therapeutics for biopharmaceutical customers.
(acquired by Wuxi PharmaTech, plc NYSE: WX; AppTec renamed WuXi AppTec, Inc.
focused on developing minimally invasive technologies designed for the prevention of atrial fibrillation related stroke.
(acquired by Boston Scientific Corporation NYSE: BSX)
is a developer of next-generation medicines with improved safety and performance and a pioneer in the targeted application of deuterium chemistry to clinically validated drugs.
developed a next generation, implantable, artificial disc employing state of the art polymer technology.
is a global leader in medical and consumer eye health.
(acquired by Valeant Pharmaceuticals International, Inc. NYSE: VRX and TSX:VRX)
focused on the development of replacement therapy based on human C-peptide for the treatment of type 1 diabetic neuropathy.
is developing new and more effective therapies for cancer based on its proprietary CombiPlex® technology.
developed high-quality pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain.
(acquired by Mallinckrodt, the Pharmaceuticals business of Covidien, NYSE: COV)
was a leader in the research and development of Toll-like receptor drugs to modulate the immune system for treating cancer, infectious diseases and asthma/allergy.
(ticker was COLY; acquired by Pfizer Inc. NYSE: PFE)
is a market leader in cryotherapy systems to treat cancerous and benign conditions.
is a developer of sterile generic and specialty pharmaceutical products.
is a licensing-focused, drug development company currently marketing Angiomax™, a novel anti-coagulant.
developed and marketed bioabsorbable, polymer scaffolds for the treatment of articular cartilage and bone defects.
(acquired by Smith & Nephew plc NYSE: SNN)
is focused on the development of pharmaceutical products for gastrointestinal and liver diseases.
developed dry powder delivery systems for the treatment of asthma and COPD.
(acquired by Sandoz, a division of Novartis AG, NYSE: NVS)
is the largest global pharmaceutical contract packager, providing cutting-edge customized healthcare packaging solutions that improve patient adherence and uphold the most stringent safety requirements
a clinical-stage biopharmaceutical company that developed novel, small molecule therapeutics for the treatment of gastrointestinal and motility disorders.
(merged with Ocera Therapeutics, Inc. NASDAQ: OCRX)
Virdante Pharmaceuticals , Inc.
focused on the development and commercialization of drugs for autoimmune and inflammatory disorders.
(acquired by Momenta Pharmaceuticals, Inc. NASDAQ: MNTA)
was acquired from Bristol-Myers Squibb Company, and manufactured and marketed products for the treatment of ear, nose and throat diseases.
(ticker was XOMD; acquired by Medtronic, Inc. ticker: MDT)
is a specialty pharmaceutical company focused on the development and commercialization of medicines to treat CNS disorders and pain, with an initial focus on SUMAVEL™ DosePro™, a needle-free migraine treatment.